Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28275596 | 1.00 | CA2 (0.40) | CA2LMNA | |
| Phosphoric Acid SCHEMBL182596 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL8505699 | 0.96 | CA2 (0.43) | CA2LMNA | |
| Phosphoric Acid SCHEMBL7601322 | 0.96 | CA2 (0.43) | CA2LMNA | |
| Phosphoric Acid SCHEMBL854955 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL6036466 | 0.96 | CA2 (0.43) | CA2LMNA | |
| Phosphoric Acid SCHEMBL6383668 | 0.96 | CA2 (0.43) | CA2LMNA | |
| Phosphoric Acid SCHEMBL17555384 | 0.96 | CA2 (0.43) | CA2LMNA | |
| Phosphoric Acid SCHEMBL675651 | 0.96 | — | — | |
| Phosphoric Acid SCHEMBL4453244 | 0.96 | CA2 (0.43) | CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993800-B2 | Process for producing optically active α-methylcysteine derivative | KANEKA CORPORATION (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20130261331-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | KANEKA CORP (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2287152-A2 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORPORATION (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100197934-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20060105435-A1 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197934-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | AHCY, CTH, BHMT | CA2 457/4885LMNA 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.